Astex Pharmaceuticals (ASTX) Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting
6/16/2014 8:49:34 AM
DUBLIN, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, presented the final results of a Phase 2 study of SGI-110, a novel hypomethylating agent in elderly Acute Myeloid Leukemia (AML) in an oral session on June 14 at the European Hematology Association meeting held in Milan, Italy (June 12-15).
Help employers find you! Check out all the jobs and post your resume.
comments powered by